Business
Voyageur Pharmaceuticals Signs LOI for Latin America Distribution Partnership Supporting Global Market Expansion
(TheNewswire) Calgary, Alberta, Canada – TheNewswire - June 24, 2025 –...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"Voyageur Pharmaceuticals Signs LOI for Latin America Distribution Partnership Supporting Global Market Expansion\n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Calgary, Alberta, Canada –\n \n\n TheNewswire -\n \n\n June 24, 2025 –\nVoyageur Pharmaceuticals Ltd.\n \n\n (TSX.V:VM) (OTC\nPink:VYYRF) (“\n \n\n Voyageur\n \n\n ”, or the “\n \n\n Company\n \n\n ”), a\nCanadian public company developing cost-effective imaging contrast\nmedia, is pleased to announce the signing of a Non-binding Letter of\nIntent (\"\n \n\n LOI\n \n\n \") with a Latin American based specialty distribution\ncompany to establish a strategic partnership for the distribution and\ncommercialization of Voyageur’s radiology contrast media products.\n \n\n\n\n The prospective partner is an established\npharmaceutical distributor with a strong presence in Mexico and other\nLatin American markets where Canadian regulatory approvals are\naccepted. Upon final agreement, the distributor will lead marketing,\nsales and regulatory activities in the region. Final terms will be\ndisclosed upon the execution of a binding distribution agreement,\nwhich is expected within 90 days.\n \n\n\n\n This partnership represents a key milestone in\nVoyageur’s international growth strategy, further expanding the\nCompany’s global footprint and supporting access to underserved\nmarkets with increasing demand for high-quality contrast media.\n“This agreement marks a significant step forward in our\ncommercialization roadmap” said Brent Willis, CEO of Voyageur. “It\nreflects our continued commitment to expanding global access to our\ninnovative, cost-effective imaging solutions. Latin America is a\ncritical market in our expansion plan, and this partnership lays the\ngroundwork for long term growth”\n \n\n\n\n Sales of Voyageur’s barium sulfate contrast media\nproducts in Mexico and other Latin American countries will be subject\nto local regulatory approval processes. The distributor is expected to\ntake the lead in preparing and submitting necessary filings with\nsupport from Voyageur’s technical and regulatory team.\n \n\n\n\n About Voyageur Pharmaceuticals\nLtd.\n \n\n\n\n Voyageur, a Canadian public company trading under the\nsymbol VM on the...